following an abbreviated submission:
vedolizumab (Entyvio®) is accepted for use within NHSScotland.
Indication under review: the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.
SMC has previously accepted vedolizumab powder for concentrate for solution for intravenous infusion for use in NHSScotland for this indication (SMC1045/15).
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice732KB (PDF)
Medicine details
- Medicine name:
- vedolizumab (Entyvio)
- SMC ID:
- SMC2276
- Indication:
Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 August 2020